Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.

The study shows that 94% of patients eliminated factor IX prophylaxis and maintained near-normal factor IX levels through ...

研究人员发现，血友病A患者的唾液中含有位于囊泡上的外源性张力酶复合体（extrinsic tenase ...

CSL Limited (OTC:CSLLY) and uniQure Inc (NASDAQ:QURE) announced the four-year results from the pivotal HOPE-B study ...

Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...

Growing advancements in haemophilia treatment underscore a significant shift toward targeted and long-lasting therapeutic ...

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...

A recent study led by MedUni Vienna provides new insights into the mechanisms of coagulation in persons with hemophilia A, the most common form of hemophilia. The research team was able to show ...

Global biotechnology leader CSL Behring (ASX:CSL; USOTC: CSLLY (OTC:CSLLY)) announced the four-year results from the HOPE-B ...

Gene therapy has been available since 2022 for hemophilia B and since 2023 for hemophilia A, yet some major medical institutions have barely treated any patients so far. What’s the holdup?

Columnist Alliah Czarielle doesn't want a person with an invisible disability to be perceived by businesses as a fraud.

Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...